RSS

deubiquitylating enzymes (DUBs)

Ubiquigent and Forma Therapeutics have entered into a multi-year strategic research and development (R&D) collaboration agreement for the design and development of novel deubiquitylase (DUB) enzyme inhibitors. more

News

Innovate UK has awarded Mission Therapeutics a £1.9 million grant for cancer treatment more

News